Citius Pharmaceuticals (CTXR)
(Delayed Data from NSDQ)
$0.36 USD
-0.01 (-3.70%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $0.36 0.00 (0.31%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
View All Zacks #1 Ranked Stocks
Citius Pharmaceuticals, Inc. (CTXR) Price Targets
| Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
|---|---|---|---|
| $4.67 | $6.00 | $4.00 | 1,162.16% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Citius Pharmaceuticals, Inc. comes to $4.67. The forecasts range from a low of $4.00 to a high of $6.00. The average price target represents an increase of 1% from the last closing price of $0.37.
Analyst Price Targets (3 )
Broker Rating
Citius Pharmaceuticals, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by three brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on three recommendations.
Of the three recommendations deriving the current ABR, three are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
| Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
| Date | Brokerage Firm | Analyst | Previous | Current |
|---|---|---|---|---|
| 9/13/2024 | Maxim Group | Michael Okunewitch | Strong Buy | Strong Buy |
| 7/15/2024 | EF Hutton Financial | Jason Kolbert | Not Available | Strong Buy |
| 5/31/2024 | H.C. Wainwright & Co. | Vernon Bernardino | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
| Current ABR | 1.00 |
| ABR (Last week) | 1.00 |
| # of Recs in ABR | 3 |
| Average Target Price | $4.67 |
| LT Growth Rate | NA |
| Industry | Medical - Drugs |
| Industry Rank by ABR | 79 of 252 |
| Current Quarter EPS Est: | -0.05 |
CTXR FAQs
Citius Pharmaceuticals, Inc. (CTXR) currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 3 brokerage firms.
The average price target for Citius Pharmaceuticals, Inc. (CTXR) is $4.67. The current on short-term price targets is based on 1 reports.
The forecasts for Citius Pharmaceuticals, Inc. (CTXR) range from a low of $4 to a high of $6. The average price target represents a increase of $1197.22 from the last closing price of $.36.
The current UPSIDE for Citius Pharmaceuticals, Inc. (CTXR) is 1197.22%
Based on short-term price targets offered by three analysts, the average price target for Citius Pharmaceuticals, Inc. comes to $4.67. The forecasts range from a low of $4.00 to a high of $6.00. The average price target represents an increase of 1% from the last closing price of $0.37.